Overview

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Status:
Completed
Trial end date:
2021-03-26
Target enrollment:
Participant gender:
Summary
A double-blind study to characterize the effect of ampreloxetine on cardiac repolarization in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Theravance Biopharma
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination